Pharma Breathes Sigh Of Relief Over Brexit Deal
'In Best Interest Of Patients In UK and EU'
The ABPI and EFPIA give a cautious welcome, but are pleased it means "ongoing collaboration in key areas including scientific research and cooperation in areas like medicines safety."
You may also be interested in...
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.